CDTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	199 489
Vidutinė apimtis	58 335.00
Rinkos kapitalizacija	57.61M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-1.500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.43
ATR14	$0.0870 (0.69%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Ward Shane	Buy	120 000	Common Stock
2024-03-15	Ward Shane	Buy	250 000	Employee Stock Option (right to buy)
2024-03-15	Shah Preetam	Buy	108 750	Common Stock
2024-03-15	Shah Preetam	Buy	217 500	Employee Stock Option (right to buy)
2024-03-15	Tari Leslie	Buy	111 250	Common Stock

INSIDER POWER
89.46
Last 100 transactions
Buy: 7 175 633 \| Sell: 576 273

Tūris Koreliacija

Ilgas: -0.10 (neutral)

Trumpas: -0.27 (neutral)

Signal:(38.021) Neutral

Cidara Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MESA	0.902
ATHX	0.885
CTIB	0.882
IGTA	0.876
HLIO	0.873
IOBT	0.859
XLNX	0.857
TITN	0.855
KZR	0.854
AZYO	0.853

10 Labiausiai neigiamai susiję koreliacijos
NTUS	-0.89
DVCR	-0.876
OPNT	-0.869
JJSF	-0.867
SVOK	-0.866
LMNX	-0.861
PROC	-0.856
STAY	-0.852
DSPG	-0.843
MSON	-0.842

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Cidara Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.49
( neutral )

0.48
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.22
( neutral )

-0.27
( neutral )

Cidara Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$63.91M
Bruto pelnas:	$62.38M (97.62 %)
EPS:	$-0.260

FY	2023
Pajamos:	$63.91M
Bruto pelnas:	$62.38M (97.62 %)
EPS:	$-0.260

FY	2022
Pajamos:	$64.29M
Bruto pelnas:	$64.15M (99.78 %)
EPS:	$-0.430

FY	2021
Pajamos:	$49.57M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.